{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T08:16:31Z","timestamp":1778400991418,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Opioid-related mortality is a rising public health concern in France, where opioids were in 2021 implicated in 75% of overdose deaths. Opioid substitution treatment (OST) was implicated in almost half of deaths related to substance and drug abuse. Although naloxone could prevent 80% of these deaths, there are a number of barriers to the distribution of take-home naloxone (THN) among opioid users in France. This study is the first one which compares patients' self-assessment of the risk of future opioid overdose with the hetero-assessment provided by healthcare professionals in a population of individuals eligible for naloxone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a multicenter descriptive observational study carried out in pharmacies across the Pays de la Loire region (France) during April and May 2022. All adult patients who visited a participating pharmacy for a prescription of OST and provided oral informed consent were enrolled in the study. Retrospective data were collected through cross-sectional interviews conducted by the pharmacist with the patient, utilizing an ad hoc questionnaire. The patient\u2019s self-assessment of overdose risk was evaluated using a Likert scale from 0 to 10. The pharmacist relied on the presence or absence of overdose risk situations defined by the French Health Authority (HAS). The need to hold THN was assessed using a composite criterion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 34 patients were interviewed; near one third were aware of the existence of THN and a minority had THN in their possession. Out of the 34 participants, 29 assessed their own risk of future opioid overdose: 65.5% reported having zero risk, while 6.9% believed they had a high risk. Nevertheless, at least one risk situation of opioid overdose was identified according to HAS criteria in 73.5% of the participants (<jats:italic>n<\/jats:italic>\u2009=\u200925). Consequently, 55% of the participants underestimated their risk of experiencing a future opioid overdose. Yet, dispensing THN has been judged necessary for 88.2% of the participants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study underscored the imperative need to inform not only healthcare professionals but also the patients and users themselves on the availability of THN and the risk situations of opioid overdose.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-00941-y","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:02:07Z","timestamp":1706000527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u201cNaloxone? Not for me!\u201d First cross-assessment by patients and healthcare professionals of the risk of opioid overdose"],"prefix":"10.1186","volume":"21","author":[{"given":"Aur\u00e9lie","family":"Aquizerate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgane","family":"Rousselet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Cochard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryl\u00e8ne","family":"Guerlais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Gerardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Duval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard-Jules","family":"Laforgue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Victorri-Vigneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"941_CR1","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. Etat des lieux de la consommation des antalgiques opio\u00efdes et leurs usages probl\u00e9matiques. Saint Denis: ANSM; 2019 f\u00e9vr"},{"issue":"4","key":"941_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/add.16081","volume":"118","author":"M Robert","year":"2023","unstructured":"Robert M, Jouanjus E, Khouri C, Fouilh\u00e9 Sam-La\u00ef N, Revol B. The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database. Addiction. 2023;118(4):771\u20135. https:\/\/doi.org\/10.1111\/add.16081.","journal-title":"Addiction"},{"key":"941_CR3","unstructured":"Association Fran\u00e7aise des Centres d\u2019Addictovigilance. D\u00e9c\u00e8s en Relation avec l\u2019Abus de M\u00e9dicaments Et de Substances n.d. http:\/\/www.addictovigilance.fr\/drames (accessed October 29, 2021)."},{"issue":"8","key":"941_CR4","doi-asserted-by":"publisher","first-page":"e2331398","DOI":"10.1001\/jamanetworkopen.2023.31398","volume":"6","author":"B Revol","year":"2023","unstructured":"Revol B, Willeman T, Manceau M, Dumestre-Toulet V, Gaulier JM, Fouilh\u00e9 Sam-La\u00ef N, et al. Trends in fatal poisoning among drug users in France from 2011 to 2021: an analysis of the DRAMES Register. JAMA Netw Open. 2023;6(8):e2331398.","journal-title":"JAMA Netw Open"},{"key":"941_CR5","unstructured":"HAS, Traitement du Trouble de l\u2019Usage d\u2019opio\u00efdes, mars 2022 (in French) [Internet]. Disponible sur: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2022-03\/traitement_du_trouble_de_lusage_dopioides_-_fiche.pdf"},{"key":"941_CR6","unstructured":"OFDT, Traitements de substitution aux opio\u00efdes en France, bilan 2023 [Internet]. Disponible sur: https:\/\/www.ofdt.fr\/BDD\/publications\/docs\/TabTSO230418.pdf"},{"key":"941_CR7","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Pr\u00e9venir et agir face aux surdoses d\u2019opio\u00efdes. Feuille de route 2019\u20132022. Paris: Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9; 2019."},{"key":"941_CR8","unstructured":"SPC Narcan, France. Disponible sur: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=64117646&typedoc=R"},{"key":"941_CR9","unstructured":"SPC Nyxoid, France [Internet]. Disponible sur: https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=63868145"},{"key":"941_CR10","unstructured":"SPC Prenoxad, France [Internet]. Disponible sur: https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=62968616"},{"key":"941_CR11","unstructured":"D\u00e9cret n\u00b0 2023-81 du 6 f\u00e9vrier 2023 relatif \u00e0 la participation des assur\u00e9s aux frais li\u00e9s \u00e0 la contraception d\u2019urgence et aux transports sanitaires."},{"issue":"5","key":"941_CR12","doi-asserted-by":"publisher","first-page":"f174","DOI":"10.1136\/bmj.f174","volume":"346","author":"AY Walley","year":"2023","unstructured":"Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2023;346(5):f174\u2013f174. https:\/\/doi.org\/10.1136\/bmj.f174.","journal-title":"BMJ"},{"key":"941_CR13","unstructured":"WHO, opioid overdose. Disponible sur: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/opioid-overdose"},{"issue":"2","key":"941_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/dar.12894","volume":"38","author":"TJ Holland","year":"2019","unstructured":"Holland TJ, Penm J, Dinh M, Aran S, Chaar B. Emergency department physicians\u2019 and pharmacists\u2019 perspectives on take-home naloxone: ED perspective on take-home naloxone. Drug Alcohol Rev. 2019;38(2):169\u201376. https:\/\/doi.org\/10.1111\/dar.12894.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"941_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1017\/cem.2017.390","volume":"20","author":"L Lacroix","year":"2018","unstructured":"Lacroix L, Thurgur L, Orkin AM, Perry JJ, Stiell IG. Emergency physicians\u2019 attitudes and perceived barriers to the implementation of take-home naloxone programs in Canadian emergency departments. CJEM. 2018;20(1):46\u201352.","journal-title":"CJEM"},{"issue":"1","key":"941_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ajad.12982","volume":"29","author":"JG Martino","year":"2020","unstructured":"Martino JG, Smith SR, Rafie S, Rafie S, Marienfeld C. Physician and pharmacist: attitudes, facilitators, and barriers to prescribing naloxone for home rescue. Am J Addict. 2020;29(1):65\u201372. https:\/\/doi.org\/10.1111\/ajad.12982.","journal-title":"Am J Addict"},{"issue":"1","key":"941_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12954-020-00375-2","volume":"17","author":"JG Salvador","year":"2020","unstructured":"Salvador JG, Sussman AL, Takeda MY, Katzman WG, Moya Balasch M, Katzman JG. Barriers to and recommendations for take-home naloxone distribution: perspectives from opioid treatment programs in New Mexico. Harm Reduct J. 2020;17(1):31. https:\/\/doi.org\/10.1186\/s12954-020-00375-2.","journal-title":"Harm Reduct J"},{"key":"941_CR18","unstructured":"HAS. Recommandation sur la Naloxone De la pr\u00e9vention du trouble de l\u2019usage et des surdoses \u00e0 la prise en charge des surdoses d\u2019opio\u00efdes. 2022."},{"key":"941_CR19","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Preventing opioid overdose deaths with take-home naloxone [Internet]. 2011 [cit\u00e9 29 oct 2021]. Disponible sur: https:\/\/www.emcdda.europa.eu\/publications\/insights\/take-home-naloxone_en"},{"key":"941_CR20","unstructured":"Stewart B. Leavitt, MA, PhD. Intranasal Naloxone for At-Home Opioid Rescue https:\/\/www.projectjj79.com\/RescueNaloxone-PPM-Oct2010-Leavitt.pdf. 2010."},{"issue":"1","key":"941_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12954-021-00521-4","volume":"18","author":"VYO Au","year":"2021","unstructured":"Au VYO, Rosic T, Sanger N, Hillmer A, Chawar C, Worster A, et al. (2021) Factors associated with opioid overdose during medication-assisted treatment: How can we identify individuals at risk? Harm Reduct J. 2021;18(1):71.","journal-title":"Harm Reduct J"},{"issue":"suppl 2","key":"941_CR22","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1111\/j.1526-4637.2011.01134.x","volume":"12","author":"LR Webster","year":"2021","unstructured":"Webster LR, Cochella S, Dasgupta N, Fakata KL, Fine PG, Fishman SM, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2021;12(suppl 2):S26-35. https:\/\/doi.org\/10.1111\/j.1526-4637.2011.01134.x.","journal-title":"Pain Med"},{"key":"941_CR23","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"key":"941_CR24","unstructured":"College of Psychiatric of Ireland. Clinical guidelines for opioid substitution treatment https:\/\/www.hse.ie\/eng\/services\/publications\/primary\/clinical-guidelines-for-opioid-substitution-treatment.pdf."},{"key":"941_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.drugpo.2017.09.015","volume":"51","author":"SC Heavey","year":"2018","unstructured":"Heavey SC, Chang YP, Vest BM, Collins RL, Wieczorek W, Homish GG. \u2018I have it just in case\u2019\u2014Naloxone access and changes in opioid use behaviours. Int J Drug Policy. 2018;51:27\u201335.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"941_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/dar.12644","volume":"37","author":"PM Dietze","year":"2018","unstructured":"Dietze PM, Stare M, Cogger S, Nambiar D, Olsen A, Burns L, et al. Knowledge of naloxone and take-home naloxone programs among a sample of people who inject drugs in Australia: variations across capital cities. Drug Alcohol Rev. 2018;37(4):457\u201363. https:\/\/doi.org\/10.1111\/dar.12644.","journal-title":"Drug Alcohol Rev"},{"key":"941_CR27","doi-asserted-by":"crossref","unstructured":"Mezaache S, Turlure F, Fredon N, Le Brun Gadelius M, Micallef J, Frauger E. Pr\u00e9vention des surdoses opio\u00efdes et diffusion de naloxone (programme POP): r\u00e9sultats d\u2019un \u00e9tat des lieux r\u00e9alis\u00e9 aupr\u00e8s des structures d\u2019addictologie. Therapies [Internet]. mars 2023 [cit\u00e9 25 mai 2023];S0040595723000574. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723000574","DOI":"10.1016\/j.therap.2023.03.008"},{"issue":"2","key":"941_CR28","doi-asserted-by":"publisher","first-page":"10868","DOI":"10.4081\/qrmh.2023.10868","volume":"7","author":"I Natale","year":"2023","unstructured":"Natale I, Harvey C, Wood P, Anderson K. \u201cIt can save your life, that\u2019s all I know\u201d, barriers and facilitators for engagement in take-home naloxone for people receiving opioid substitution treatment in regional Australia: an explorative study. Qual Res Med Healthc. 2023;7(2):10868.","journal-title":"Qual Res Med Healthc"},{"issue":"1","key":"941_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/dar.13144","volume":"40","author":"B Moradmand-Badie","year":"2021","unstructured":"Moradmand-Badie B, Tran L, Oikarainen N, Degenhardt L, Nielsen S, Roberts J, et al. Feasibility and acceptability of take-home naloxone for people released from prison in New South Wales, Australia. Drug Alcohol Rev. 2021;40(1):98\u2013108. https:\/\/doi.org\/10.1111\/dar.13144.","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"941_CR30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.therap.2022.10.047","volume":"77","author":"L Charuel","year":"2022","unstructured":"Charuel L, H\u00e9r\u00e9dia J, Lazic J, Giband C, Fortias M, Spejchal M, et al. La naloxone sauve des vies\u202f: qu\u2019en pensent les usagers\u202f? Therapies. 2022;77(6):778\u20139.","journal-title":"Therapies"},{"key":"941_CR31","doi-asserted-by":"crossref","unstructured":"Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacol Ther [Internet]. oct 2021 [cit\u00e9 24 avr 2022];108019. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821002217","DOI":"10.1016\/j.pharmthera.2021.108019"},{"key":"941_CR32","unstructured":"Gouvernement du Qu\u00e9bec. Risques li\u00e9s \u00e0 l\u2019usage d\u2019opioides https:\/\/www.quebec.ca\/sante\/conseils-et-prevention\/alcool-drogues-jeu\/risques-lies-a-l-usage-d-opioides. 2020."},{"key":"941_CR33","unstructured":"OMS. surdose d\u2019opioides https:\/\/www.who.int\/fr\/news-room\/fact-sheets\/detail\/opioid-overdose. 2021."},{"key":"941_CR34","unstructured":"Schiller EY, Goyal A, Mechanic OJ. Opioid Overdose. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cit\u00e9 24 avr 2022]. Disponible sur: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470415\/"},{"key":"941_CR35","doi-asserted-by":"publisher","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ [Internet]. 26 avr 2017 [cit\u00e9 24 avr 2022];j1550. Disponible sur: https:\/\/doi.org\/10.1136\/bmj.j1550","DOI":"10.1136\/bmj.j1550"},{"key":"941_CR36","unstructured":"Linda Gowing. National Guidelines for Medication-Assisted Treatment of Opioid Dependence in AUSTRALIA https:\/\/www.health.gov.au\/sites\/default\/files\/national-guidelines-for-medication-assisted-treatment-of-opioid-dependence.pdf."},{"issue":"4","key":"941_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.mcna.2018.02.005","volume":"102","author":"SL Peglow","year":"2018","unstructured":"Peglow SL, Binswanger IA. Preventing opioid overdose in the clinic and hospital. Med Clin North Am. 2018;102(4):621\u201334.","journal-title":"Med Clin North Am"},{"issue":"12","key":"941_CR38","doi-asserted-by":"publisher","first-page":"e1003002","DOI":"10.1371\/journal.pmed.1003002","volume":"16","author":"M Malta","year":"2019","unstructured":"Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. Tsai AC, \u00e9diteur. PLOS Med. 2019;16(12):e1003002. https:\/\/doi.org\/10.1371\/journal.pmed.1003002.","journal-title":"PLOS Med"},{"issue":"13","key":"941_CR39","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s40265-019-01154-5","volume":"79","author":"J Strang","year":"2019","unstructured":"Strang J, McDonald R, Campbell G, Degenhardt L, Nielsen S, Ritter A, et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs. 2019;79(13):1395\u2013418. https:\/\/doi.org\/10.1007\/s40265-019-01154-5.","journal-title":"Drugs"},{"key":"941_CR40","doi-asserted-by":"publisher","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Preventing opioid overdose deaths with take-home naloxone. [Internet]. LU: Publications Office; 2016 [cit\u00e9 24 avr 2022]. Disponible sur: https:\/\/doi.org\/10.2810\/357062","DOI":"10.2810\/357062"},{"issue":"6","key":"941_CR41","first-page":"432","volume":"6","author":"LR Webster","year":"2005","unstructured":"Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med Malden Mass d\u00e9c. 2005;6(6):432\u201342.","journal-title":"Pain Med Malden Mass d\u00e9c"},{"issue":"4\u20135","key":"941_CR42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0001-4079(19)30677-6","volume":"200","author":"B M\u00e9garbane","year":"2016","unstructured":"M\u00e9garbane B. Overdose aux opioids: pr\u00e9sentation clinique et place de la naloxone. Bull Acad\u00e9mie Natl M\u00e9decine. 2016;200(4\u20135):843\u201356.","journal-title":"Bull Acad\u00e9mie Natl M\u00e9decine"},{"issue":"3","key":"941_CR43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jpain.2011.11.004","volume":"13","author":"KW Saunders","year":"2012","unstructured":"Saunders KW, Von Korff M, Campbell CI, Banta-Green CJ, Sullivan MD, Merrill JO, Weisner C. Concurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors. J Pain. 2012;13(3):266\u201375. https:\/\/doi.org\/10.1016\/j.jpain.2011.11.004.","journal-title":"J Pain"},{"key":"941_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j760","author":"EC Sun","year":"2017","unstructured":"Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017. https:\/\/doi.org\/10.1136\/bmj.j760.","journal-title":"BMJ"},{"key":"941_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12635","author":"DEA Deering","year":"2018","unstructured":"Deering DEA, Adamson SJ, Sellman JD, Henderson C, Sheridan J, Pooley S, et al. Potential risk for fatal drug overdose perceived by people using opioid drugs. Drug Alcohol Rev. 2018. https:\/\/doi.org\/10.1111\/dar.12635.","journal-title":"Drug Alcohol Rev"},{"key":"941_CR46","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2015.12.018","volume":"159","author":"C Rowe","year":"2016","unstructured":"Rowe C, Santos GM, Behar E, Coffin PO. Correlates of overdose risk perception among illicit opioid users. Drug Alcohol Depend. 2016;159:234\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"941_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12954-018-0255-5","volume":"15","author":"M Curtis","year":"2018","unstructured":"Curtis M, Dietze P, Aitken C, Kirwan A, Kinner SA, Butler T, et al. Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use. Harm Reduct J. 2018;15(1):48. https:\/\/doi.org\/10.1186\/s12954-018-0255-5.","journal-title":"Harm Reduct J"},{"issue":"1","key":"941_CR48","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s13104-016-2268-z","volume":"9","author":"ML Drainoni","year":"2016","unstructured":"Drainoni ML, Koppelman EA, Feldman JA, Walley AY, Mitchell PM, Ellison J, et al. Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment. BMC Res Notes. 2016;9(1):465. https:\/\/doi.org\/10.1186\/s13104-016-2268-z.","journal-title":"BMC Res Notes"},{"issue":"1","key":"941_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1477-7517-3-19","volume":"3","author":"N Worthington","year":"2006","unstructured":"Worthington N, Markham Piper T, Galea S, Rosenthal D. Opiate users\u2019 knowledge about overdose prevention and naloxone in New York City: a focus group study. Harm Reduct J. 2006;3(1):19. https:\/\/doi.org\/10.1186\/1477-7517-3-19.","journal-title":"Harm Reduct J"},{"key":"941_CR50","unstructured":"University of Massachusetts Medical School, Department of Emergency Medicine, Worcester, Massachusetts, Lai J, Goldfine C, Chapman B, Taylor M, Rosen R, et al. Nobody Wants to Be Narcan\u2019d: A Pilot Qualitative Analysis of Drug Users\u2019 Perspectives on Naloxone. West J Emerg Med 22(2). Disponible sur: https:\/\/escholarship.org\/uc\/item\/26f513kn"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00941-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00941-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00941-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:08:14Z","timestamp":1706000894000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00941-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00941-y","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"4 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Nantes Health Ethics Group (approval number: 22-3-110). In accordance with current French law, an information note on the study was provided to participants and their oral consent was received.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants gave oral consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}